A narrative review found that while cannabinoids show some benefits for pain in rheumatoid arthritis, osteoarthritis, and fibromyalgia, drug interactions with common rheumatology medications and adverse effects tilt the balance toward caution.
Rheumatology patients using or considering cannabis for pain, rheumatologists, and pharmacists monitoring drug interactions.
613 articles screened; drug interactions identified with common RA medications
What the researchers found
Cannabinoids act through CB1 and CB2 receptors with potential analgesic effects. Some benefits were found for rheumatoid arthritis, osteoarthritis, and fibromyalgia. However, cannabinoids have potential interactions with common rheumatology drugs that many users are unaware of, and the review concluded on balance that cannabinoids are more "foe" than "friend" for rheumatology.
Why it matters
Rheumatology patients increasingly use cannabinoids for pain without prescription, often unaware of potential interactions with their prescribed medications. This review directly addresses a knowledge gap in clinical practice.
The numbers in context
613 articles screened. Two major cannabinoid receptor types (CB1, CB2) reviewed. Despite NHS guidelines against cannabinoid use for chronic pain, patients increasingly use them without prescriptions.
How the study worked
Narrative review searching PubMed for "Cannabinoids," "Rheumatology," and "Chronic pain." Screened 613 articles for mechanism of action, adverse effects, and drug interactions. Included musculoskeletal librarian consultation.
What this study cannot tell us
Narrative review methodology is less rigorous than systematic review. Concluded "foe" based on risk-benefit balance, which involves subjective judgment. Drug interaction evidence is primarily theoretical for many rheumatology medications.
How to read the evidence
Narrative review covering mechanism, efficacy, and drug interactions, but without systematic methodology.
When this study was published
Published in 2022.
The bigger picture
The disconnect between patient behavior (using cannabinoids for pain relief) and clinical guidelines (recommending against it) creates a practical challenge. The drug interaction risks add an additional layer of concern for patients on multiple medications.
Questions still open
- Which specific rheumatology drugs have the most dangerous interactions with cannabinoids? Could monitored cannabinoid use be safer than unmonitored self-medication?
Common questions
Can cannabis help with arthritis pain?
Does cannabis interact with arthritis medications?
Read the original research
Cannabinoids in rheumatology: Friend, foe or a bystander?
Musculoskeletal care, 20(2), 416-428
Citation
Jain, Nibha; Moorthy, Arumugam. (2022). Cannabinoids in rheumatology: Friend, foe or a bystander?. Musculoskeletal care, 20(2), 416-428. https://doi.org/10.1002/msc.1636
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk
- THC and Painkillers: Opioid Interactions and the Harm Reduction Angle
- THC and Muscle Relaxers: What You Need to Know About Combining Them
- THC and Ibuprofen: Safe to Combine? What the Research Says